| Literature DB >> 26839544 |
Chen Jian-Hui1, Cai Shi-Rong1, Wu Hui1, Xu Jian-Bo1, Wu Kai-Ming1, Chen Si-le1, Yu-Long He1.
Abstract
MC tended toward worse tumor biological behavior and long-term survival outcome compared to WMDC. Moreover, MC also showed worse clinicopathological features and survival outcome in some selected patients. For these reasons, MC should be deemed as a special histological type of gastric cancer with worse clinicopathological features and survival outcome.Entities:
Year: 2015 PMID: 26839544 PMCID: PMC4709619 DOI: 10.1155/2016/8947505
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Comparison of clinicopathological features between MC and WMDC patients for gastric cancer.
| MC (68 cases) | WMDC (329 cases) |
|
| |
|---|---|---|---|---|
| Age | 0.571 | 0.450 | ||
| ≤60 years | 34 (50.0%) | 148 (45.0%) | ||
| >60 years | 34 (50.0%) | 181 (55.0%) | ||
| Gender | 3.513 | 0.061 | ||
| Male | 44 (64.7%) | 249 (75.5%) | ||
| Female | 24 (35.3%) | 80 (24.3%) | ||
| Tumor diameter | 8.867 | 0.003 | ||
| ≤5 cm | 28 (41.2%) | 200 (60.8%) | ||
| >5 cm | 40 (58.8%) | 129 (39.2%) | ||
| Tumor location | 1.470 | 0.479 | ||
| Upper 1/3 | 25 (36.8%) | 132 (40.1%) | ||
| Middle 1/3 | 7 (10.3%) | 47 (14.3%) | ||
| Lower 1/3 | 36 (52.9%) | 150 (45.6%) | ||
| Borrmann type | 7.399 | 0.060 | ||
| Borrmann I | 8 (11.8%) | 30 (9.1%) | ||
| Borrmann II | 12 (17.6%) | 113 (34.3%) | ||
| Borrmann III | 41 (60.3%) | 162 (49.2%) | ||
| Borrmann IV | 7 (10.3%) | 24 (7.3%) | ||
| Depth of invasion | 22.274 | <0.001 | ||
| T1 | 2 (2.9%) | 60 (18.2%) | ||
| T2 | 7 (10.3%) | 77 (23.4%) | ||
| T3 | 33 (48.5%) | 125 (38.0%) | ||
| T4 | 26 (38.2%) | 67 (20.4%) | ||
| Lymph node metastasis | 10.130 | 0.017 | ||
| N0 | 13 (19.1%) | 121 (36.8%) | ||
| N1 | 15 (22.1%) | 76 (23.1%) | ||
| N2 | 23 (33.8%) | 82 (24.9%) | ||
| N3 | 17 (25.0%) | 50 (15.2%) | ||
| TNM stage | 10.827 | 0.013 | ||
| I | 6 (8.8%) | 82 (24.9%) | ||
| II | 11 (16.2%) | 58 (17.6%) | ||
| III | 28 (41.2%) | 119 (36.2%) | ||
| IV | 23 (33.8%) | 70 (21.3%) | ||
| Peritoneal dissemination | 11.849 | 0.001 | ||
| P (+) | 20 (29.4%) | 42 (12.8%) | ||
| P (−) | 48 (70.6%) | 287 (87.2%) | ||
| Hepatic metastasis | 0.386 | 0.535 | ||
| H (+) | 3 (4.4%) | 21 (6.4%) | ||
| H (−) | 65 (95.6%) | 308 (93.6%) | ||
| Curability | 6.440 | 0.011 | ||
| Curative | 43 (63.2%) | 256 (77.8%) | ||
| Noncurative | 25 (36.8%) | 73 (22.2%) |
Comparison of clinicopathological features between MC and PDC patients for gastric cancer.
| MC (68 cases) | PDC (599 cases) |
|
| |
|---|---|---|---|---|
| Age | 4.936 | 0.026 | ||
| ≤60 years | 34 (50.0%) | 382 (63.8%) | ||
| >60 years | 34 (50.0%) | 217 (36.2%) | ||
| Gender | 0.032 | 0.858 | ||
| Male | 44 (64.7%) | 381 (63.6%) | ||
| Female | 24 (35.3%) | 218 (36.4%) | ||
| Tumor diameter | 2.318 | 0.128 | ||
| ≤5 cm | 28 (41.2%) | 305 (50.9%) | ||
| >5 cm | 40 (58.8%) | 294 (49.1%) | ||
| Tumor location | 3.271 | 0.195 | ||
| Upper 1/3 | 25 (36.8%) | 185 (30.9%) | ||
| Middle 1/3 | 7 (10.3%) | 115 (19.2%) | ||
| Lower 1/3 | 36 (52.9%) | 299 (49.9%) | ||
| Borrmann type | 5.997 | 0.112 | ||
| Borrmann I | 8 (11.8%) | 52 (8.7%) | ||
| Borrmann II | 12 (17.6%) | 191 (31.9%) | ||
| Borrmann III | 41 (60.3%) | 301 (50.3%) | ||
| Borrmann IV | 7 (10.3%) | 55 (9.2%) | ||
| Depth of invasion | 7.864 | 0.049 | ||
| T1 | 2 (2.9%) | 59 (9.8%) | ||
| T2 | 7 (10.3%) | 101 (16.9%) | ||
| T3 | 33 (48.5%) | 280 (46.7%) | ||
| T4 | 26 (38.2%) | 159 (26.5%) | ||
| Lymph node metastasis | 5.435 | 0.143 | ||
| N0 | 13 (19.1%) | 161 (26.9%) | ||
| N1 | 15 (22.1%) | 172 (28.7%) | ||
| N2 | 23 (33.8%) | 142 (23.7%) | ||
| N3 | 17 (25.0%) | 124 (20.7%) | ||
| TNM stage | 3.514 | 0.319 | ||
| I | 6 (8.8%) | 95 (15.8%) | ||
| II | 11 (16.2%) | 115 (19.2%) | ||
| III | 28 (41.2%) | 228 (38.1%) | ||
| IV | 23 (33.8%) | 161 (26.9%) | ||
| Peritoneal dissemination | 5.858 | 0.016 | ||
| P (+) | 20 (29.4%) | 104 (17.4%) | ||
| P (−) | 48 (70.6%) | 495 (82.6%) | ||
| Hepatic metastasis | 0.001 | 0.971 | ||
| H (+) | 3 (4.4%) | 27 (4.5%) | ||
| H (−) | 65 (95.6%) | 572 (95.5%) | ||
| Curability | 1.433 | 0.231 | ||
| Curative | 43 (63.2%) | 421 (70.3%) | ||
| Noncurative | 25 (36.8%) | 178 (29.7%) |
Survival comparisons between MC and WMDC patients for gastric cancer.
| WMDC | MC |
|
| |
|---|---|---|---|---|
| Total | 12.61 | 0.004 | ||
| 1-year OS rate | 83.4% | 64.3% | ||
| 3-year OS rate | 60.5% | 37.1% | ||
| 5-year OS rate | 50.9% | 29.4% | ||
| Early stage | 0.676 | 0.411 | ||
| 1-year OS rate | 100.0% | 100.0% | ||
| 3-year OS rate | 95.5% | 100.0% | ||
| 5-year OS rate | 92.5% | 100.0% | ||
| Advanced stage | 5.741 | 0.017 | ||
| 1-year OS rate | 79.8% | 63.2% | ||
| 3-year OS rate | 52.3% | 34.8% | ||
| 5-year OS rate | 41.6% | 26.5% |
OS: overall survival.
Figure 1Survival comparison between MC and WMDC patients. (a) Total patients. (b) Patients in the early stage. (c) Patients in the advanced stage.
Survival comparisons between MC and PDC patients for gastric cancer.
| PDC | MC |
|
| |
|---|---|---|---|---|
| Total | 2.020 | 0.155 | ||
| 1-year OS rate | 72.2% | 64.3% | ||
| 3-year OS rate | 47.9% | 37.1% | ||
| 5-year OS rate | 38.4% | 29.4% | ||
| Early stage | 0.402 | 0.526 | ||
| 1-year OS rate | 100.0% | 100.0% | ||
| 3-year OS rate | 89.5% | 100.0% | ||
| 5-year OS rate | 85.0% | 100.0% | ||
| Advanced stage | 0.837 | 0.360 | ||
| 1-year OS rate | 69.2% | 63.2% | ||
| 3-year OS rate | 43.6% | 34.8% | ||
| 5-year OS rate | 33.7% | 26.5% |
OS: overall survival.
Figure 2Survival comparison between MC and PDC patients. (a) Total patients. (b) Patients in the early stage. (c) Patients in the advanced stage.
Figure 3Subgroup survival comparison between MC and PDC patients. (a) Patients with ages ≦ 60 years (P = 0.046). (b) Patients with tumor diameter ≦ 5 cm (P = 0.029). (c) Patients with Borrmann type III (P = 0.023).
Significant subgroup survival comparisons between MGC and PDC patients.
| MGC | PDC |
|
| |
|---|---|---|---|---|
| Age ≤ 60 years | 3.968 | 0.046 | ||
| 1-year OS rate | 64.7% | 75.2% | ||
| 3-year OS rate | 34.7% | 51.6% | ||
| 5-year OS rate | 26.0% | 40.7% | ||
| Tumor diameter ≤ 5 cm | 4.796 | 0.029 | ||
| 1-year OS rate | 60.7% | 85.9% | ||
| 3-year OS rate | 45.5% | 68.3% | ||
| 5-year OS rate | 40.5% | 56.6% | ||
| Borrmann III type | 5.152 | 0.023 | ||
| 1-year OS rate | 55.3% | 70.8% | ||
| 3-year OS rate | 30.5% | 46.4% | ||
| 5-year OS rate | 22.8% | 36.6% |
Cox regression analysis results for gastric cancer.
| Factors | Univariate regression analysis | Multivariate regression analysis | ||||
|---|---|---|---|---|---|---|
| RR | 95% CI |
| RR | 95% CI |
| |
| Elder age | 1.222 | 1.022–1.461 | 0.028 | 1.341 | 1.118–1.610 | 0.002 |
| Gender | 0.689 | — | 0.407 | |||
| Tumor diameter | 2.999 | 2.487–3.616 | <0.001 | 1.560 | 1.283–1.896 | <0.001 |
| Histological type | 1.144 | 1.051–1.246 | 0.002 | |||
| Tumor location | 0.199 | — | 0.655 | |||
| Borrmann type | 2.068 | 1.814–2.358 | <0.001 | |||
| Depth of invasion | 2.891 | 2.519–3.318 | <0.001 | |||
| Lymph nodes metastasis | 2.899 | 2.535–3.316 | <0.001 | 1.719 | 1.447–2.041 | <0.001 |
| TNM stage | 1.986 | 1.851–2.130 | <0.001 | 1.374 | 1.242–1.520 | <0.001 |
| Adjuvant chemotherapy | 0.740 | 0.601–0.910 | 0.004 | 0.752 | 0.607–0.931 | 0.009 |
| Radical resection | 6.705 | 5.530–8.129 | <0.001 | 2.453 | 1.945–3.095 | <0.001 |